Craig C. Hopkinson - 22 Feb 2025 Form 4 Insider Report for Alkermes plc. (ALKS)

Role
EVP R&D, Chief Medical Officer
Signature
/s/ Stephanie Roche, attorney-in-fact for Craig C. Hopkinson
Issuer symbol
ALKS
Transactions as of
22 Feb 2025
Net transactions value
-$313,147
Form type
4
Filing time
25 Feb 2025, 18:35:58 UTC
Previous filing
20 Feb 2025
Next filing
28 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALKS Ordinary Shares Options Exercise +12,279 +20% 75,100 22 Feb 2025 Direct F1
transaction ALKS Ordinary Shares Tax liability $192,565 -5,452 -7.3% $35.32 69,648 22 Feb 2025 Direct
transaction ALKS Ordinary Shares Options Exercise +7,689 +11% 77,337 23 Feb 2025 Direct F1
transaction ALKS Ordinary Shares Tax liability $120,582 -3,414 -4.4% $35.32 73,923 23 Feb 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALKS Restricted Stock Unit Award Options Exercise -12,279 -100% 0 22 Feb 2025 Ordinary Shares 12,279 Direct F1, F2
transaction ALKS Restricted Stock Unit Award Options Exercise -7,689 -33% 15,379 23 Feb 2025 Ordinary Shares 7,689 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one ordinary share.
F2 This award is fully vested in accordance with its terms.
F3 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.